Markets:

Overview

News

Currencies

International

Treasuries

Merck Kgaa (OP:MKGAF)

162.72 +8.02 (+5.18%)

Streaming Delayed Price Updated: 11:34 AM EDT, Jul 22, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Merck Kgaa

Invo Fertility Stock Is Plunging After White House Announcement ↗

October 17, 2025

INVO Fertility Inc (NASDAQ:IVF) shares are trading lower on Thursday as investors book profits following White House announcements aimed at making fertility treatments more affordable and accessible.

Via Benzinga

FDA Unveils First Experimental Drugs Under Fast-Track Voucher Plan To Cut Drug Review Times ↗

October 17, 2025

The FDA launched a new voucher program to fast-track reviews, naming nine experimental drugs for cancer, diabetes, addiction, and other conditions.

Via Benzinga

EMD Serono, CVS Health To Partner On TrumpRx Fertility Program Launching In 2026 ↗

October 17, 2025

Trump and EMD Serono strike a deal to cut fertility drug costs, expand U.S. manufacturing, and launch the TrumpRx Fertility program in 2026.

Via Benzinga

Topics Government

Prediction: 2 Stocks That Will Be Worth More Than BigBear.ai 5 Years From Now ↗

September 26, 2025

BigBear.ai is bigger than both of these AI-focused companies now. That could change.

Via The Motley Fool

Topics Artificial Intelligence

Avantor Stock Jumps As Activist Investor Urges Sale, Board Shake-Up, And Cost Cuts ↗

August 11, 2025

Engine Capital, holding a 3% stake in Avantor, urges the board to pursue a turnaround or sale, citing years of underperformance, missed targets, and lost market share.

Via Benzinga

Crown Bioscience San Diego Achieves CLIA Certification to Enhance Clinical Trial Support

July 22, 2025

From Crown Bioscience

Via JCN Newswire

WeRide, CRISPR And GeneDx Are Among Top 10 Mid-Cap Gainers Last Week (Feb 10-Feb 14): Are The Others In Your Portfolio? ↗

February 16, 2025

Top performing mid-cap stocks last week: WRD (+97.62%), GDS (+43.45%), SWTX (+42.58%), RXRX (+40.59%), SOC (+39.09%), WGS (+28.23%), VNET (+28.22%), NSP (+25.99%), CRSP (+25.21%), AXSM (+24.01%)

Via Benzinga

Germany's Merck In Talks To Buy Cancer Drug Maker SpringWorks Therapeutics ↗

February 11, 2025

Merck KGaA is in advanced talks to acquire SpringWorks, whose portfolio could bolster Merck's oncology business amid patent expirations and competition.

Via Benzinga

Topics Intellectual Property

GSK To Buy US-Based Stomach Cancer Drug Developer For Over $1 Billion ↗

January 13, 2025

GSK's $1 billion acquisition of IDRx includes IDRX-42, a precision therapy for GIST. Phase 1/1b trial shows 53% ORR in early treatment stages.

Via Benzinga

Week In Review: Eisai Enters $1.5 Billion Molecular Glues Pact With SEED ↗

August 17, 2024

Japan’s Eisai Pharma formed a collaboration with SEED, a Pennsylvania biotech, to develop molecular glues for targeted protein degradation of disease-causing proteins. SEED is eligible to receive up to...

Via Talk Markets

Merck Germany's Two Pivotal Trials Flunk In Multiple Sclerosis ↗

December 06, 2023

Merck KGaA (OTC: MKGAF) (OTC:

Via Benzinga

Week In Review: Hengrui Out-Licenses Next-Gen PARP1 To Merck KGaA For $1.7 Billion ↗

November 04, 2023

Jiangsu Hengrui Pharma out-licensed global rights for its next-gen PARP1 inhibitor to Germany’s Merck KGaA for a $170 million upfront payment and up to $1.5 billion in milestones. Merck will have...

Via Talk Markets

Life Sciences Player Repligen's Strategic European Acquisition - What It Means for Investors ↗

September 26, 2023

Repligen Corporation (NASDAQ: RGEN) agreed to acquire Sweden-based privately-held Metenova.

Via Benzinga

Merck Germany Reports 5% Decline In Q2 Sales, Expects More Decline In 2023 ↗

August 03, 2023

Merck KGa Germany (OTC: MKGAF) (OTC: MKKGY) reported

Via Benzinga

Novo Nordisk's Obesity Drug Saxenda Not Included In WHO's Essential Drug List ↗

July 26, 2023

The World Health Organization (WHO) published the new editions of the Model Lists of Essential Medicines (EML) and Essen

Via Benzinga

Abcam Downgrade: Analyst Trims Expectations Amid Activist Investor Engagement and Potential Bid Anticipation ↗

June 20, 2023

RBC Capital Markets has downgraded Abcam PLC (NASDAQ: ABCM) from Outperform to Sector Perform with a price target of $22,

Via Benzinga

Roche's Investigational Drug For Relapsing Multiple Sclerosis Reduces Brain Lesions, Data Shows ↗

May 17, 2023

Roche Holdings AG's (OTC: RHHBY) Phase 2 FENopta study of oral fenebrutinib for relapsing forms of multiple sclerosis (RMS)

Via Benzinga

Analyst Says Nektar Therapeutics' Rezpeg Prioritization Likely to Spark Investor Questions ↗

April 18, 2023

Via Benzinga

FDA Issues Partial Clinical Hold On Merck Germany's Multiple Sclerosis Study ↗

April 12, 2023

Via Benzinga

Merck Germany Regains Exclusive Global Rights To Cancer Drug From Pfizer ↗

March 27, 2023

Via Benzinga

Incyte Would Now Compete With Merck, Pfizer As Its Skin Cancer Treatment Scores FDA Accelerated Approval ↗

March 23, 2023

Via Benzinga

PDS Biotech, Merck Germany Enter Licensing Pact For Investigational Cancer Treatment ↗

January 03, 2023

Via Benzinga

Mersana Inks Cancer Therapy Development Deal With Merck Germany ↗

December 23, 2022

Via Benzinga

GlaxoSmithKline, Merck KGaA End $4B Cancer Drug Pact ↗

September 30, 2021

Merck KGaA (OTC: MKGAF) and GlaxoSmithKline Plc (NASDAQ: GSK) have ended their $4 billion collaboration on cancer treatment, bintrafusp alfa. Merck said...

Via Benzinga

Nektar, Merck Germany, Pfizer Join Forces For Mid-Stage Bladder Cancer Study ↗

September 21, 2021

Nektar Therapeutics Inc (NASDAQ: NKTR) has entered into a new oncology clinical collaboration with Merck KGaA (OTC: MKGAF) and Pfizer Inc (NYSE...

Via Benzinga

Merck KGaA Pulls Plug On GSK-Partnered Cancer Drug Trial ↗

August 24, 2021

Merck KGaA's (OTC: MKGAF) announced that a Phase 2 trial of bintrafusp alfa had been discontinued, as an independent data monitoring committee has determined the...

Via Benzinga

Sutro Biopharma Receives Undisclosed Milestone Payment Under Bispecific ADC Collaboration with Merck ↗

June 01, 2021

Sutro Biopharma Inc (NASDAQ: STRO) has received a milestone payment under its collaboration and license agreement with the healthcare division of Merck KGaA...

Via Benzinga

Immutep, Merck Germany Team Up for Eftilagimod/Bintrafusp Combo Trial In Solid Tumors ↗

June 01, 2021

Immutep Limited (NASDAQ: IMMP) has announced a new collaboration and supply agreement with Germany-based Merck KGaA (OTC: MKGAF) for a Phase 1/2a INSIGHT...

Via Benzinga

Gene Therapy Player Vera Therapeutics Prices IPO Well Below Range At $11/Share ↗

May 14, 2021

Vera Therapeutics Inc has priced its 4.35 million share IPO at $11 per share, well below its targeted range of $14 to $16, raising $47.58 million in gross proceeds. The...

Via Benzinga

Topics Initial Public Offering

UK's NICE Provisionally Rejects Coverage Of Pfizer-Merck KGaA's Bavencio As First-Line Therapy For Bladder Cancer ↗

May 10, 2021

England’s drug-cost watchdog has shown a cold-shoulder to Pfizer Inc (NYSE: PFE) and Merck KGaA’s (OTCMKTS: MKGAF) Bavencio (avelumab) as...

Via Benzinga

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Merck Kgaa (OP:MKGAF)

All News about Merck Kgaa

Starting at /week.